The AGBT meeting ended a few days ago. Many exciting announcements were made, most of them related to technological aspects in the field of NGS. AGBT was also the stage for relevant biomedical projects. The New York Genome Center (NYGC), for instance, decided to reveal its future plans right there. The brand new center, as stated by its director Nancy Kelley, is planning to start its research activity with a challenging large-scale sequencing project. In collaboration with the Feinstein Institute for Medical Research and Illumina, NYGC is starting to sequence 130 genomes from Alzheimer patients and the number will reach the 1,000 over the next 4 years. The study will include the sequencing of an healthy elderly control group and all the data will be made freely available. The goal of the project is to understand the genetic basis of susceptibility to Alzheimer’s disease, of which very little is currently known. “The Feinstein Institute’s commitment to sharing the data resulting from these efforts with the greater research community could significantly accelerate the speed of translational research in Alzheimer’s disease, with a profound impact on patient care and clinical outcomes, which is in line with the vision of NYGC” director Nancy Kelley said. Here is the link to the NYGC press release.
No comments:
Post a Comment